Gefos-Publikationsübersicht

Transkript

1 Gefos-Publikationsübersicht Stand: Distribution of therapy regimen in patients with B-cell chronic lymphocytic leukemia (B-CLL) in 2015 in comparison to treatment strategies in 2012 based on real-world-evidence data of German oncological practices Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R Abstract P861. Oncol Res Treat 2016; 39 (suppl3): 258 A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC a comparison of NGM and TCGA LUSC data Koleczko S, Schäpers C, Scheffler M, Ihle M, Kostenko A,, Michels S, Fischer R, Nogova L,, Serke M, Kaminsky B, Benedikter J, Brümmendorf TH, Ficker JH, Lorenz J,, Schulte C, Schulze-Olden S, Brandes V, Abdulla D, Ueckeroth F, Thurat M, Merkelbach-Bruse S, Büttner R, Wolf J Abstract V134. Oncol Res Treat 2016; 39 (suppl3): 32 Treatment results of 13 years CML therapy in a private office. A contribution of the German CML Alliance Kämpfe D, Haverkamp T, Heil G, Schulte C, Tesch H, Stein H, Die Deutsche CML-Allianz Abstract P215. Oncol Res Treat 2016; 39 (suppl3): 59 Cost analysis of patients with relapsed or refractory multiple myeloma (MM) based on real-worldevidence data of German oncological practices Feuerbach M, Freigang F, Schulte C, Hurtz H-J, Schwarzer A, Lipp R Abstract P550. Oncol Res Treat 2016; 39 (suppl3): 164 Analysis of potentially targetable mutations in 1056 patients with squamous cell lung cancer undergoing routine NGS-based molecular diagnostics Koleczko S, Scheffler M, Steinhauser S, Kostenko A, Schäpers C, Michels S, Fischer R, Brandes V, Abdulla D, Nogova L, Ueckeroth F, Thurat M, Serke M, Kaminsky B, Gerigk U, Benedikter J, 1

2 Brümmendorf T, Ficker JH, Kruis W, Lorenz J, Schulte C, Schulze-Olden S, Merkelbach-Bruse S, Büttner R, Wolf J Abstract P. 17th World Conference on Lung Cancer Dec , Wien Prognosis of myelodysplastic syndrome (MDS) in patients in the age of 80 years and older: Data from the Regular Care MDS Registry in Germany. Steinmetz HAT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S Blood 2016; 128:4333 Abstract P th Ann Meeting Am Soc Hem Dec , San Diego, CA Abstract P220. Jahrestagung DGHO Oct , Leipzig Mutation profiling and consecutive treatment decisions under knowledge of mutation results in patients with metastatic colorectal cancer (mcrc) in real world evidence (RWE) of oncological practices first results of the GO-KOLORAS registry study Lipp R, Freigang F, Brecht P, Schwaner I, Steinmetz T, Schulte C, Tiemann M Abstract P309. Oncol Res Treat 2016; 39 (suppl3): 97 Abstract: A Jahrestagung der DGHO, OeGHO, SSMO, SSOM, SGMO und SGHSSH Oct , Leipzig Efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase: Results of the 4 th interim analysis of the non-interventional MOMENT II-study. Sauer A, Lathan B, Tebbe S, Ulshöfer T, Lange E, Schulze M, Nusch A, Janssen J, Losem C, Meincke M, Rupprecht S, Tesch H Abstract P211. Oncol Res Treat 2016; 39 (suppl3): 52 Abstract P211. Jahrestagung DGHO Oct , Leipzig Three years after the start of enrolment: Current data from the prospective chronic lymphocytic leukemia (CLL)-registry of the German CLL Study Group. Fink AM, Maurer C, Bahlo J, Kluth S, Linde H, Aldaoud A, Illmer T, Dengler J, Klausmann M, Lathan B, Al-Sawaf O, Fischer K, Wendtner CM, Eichhorst B, Hallek M Abstract P855. Oncol Res Treat 2016; 39 (suppl3): 256 Abstract P. Jahrestagung DGHO Oct , Leipzig The relevance of the international prognostic scoring system (IPSS) for patients with myelodysplasia (MDS) at higher age. Steinmetz HT, Wahdat R, Haastert B, Sauer A, Lathan B, Lerchenmüller C, Tesch H, Germing U, Schmitz S 2

3 Abstract P220. Oncol Res Treat 2016; 39 (suppl3): 61 Abstract P. Jahrestagung DGHO Oct , Leipzig Clinical characteristics and long-term outcome of myeloid/lymphoid neoplasms with PDGFRB fusion genes in chronic or blast phase. Jawhar M, Naumann N, Schwaab J, Dietz C, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lofti S, Luber V, Maywald O, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Schmitt K, Baurmann H, Vieler T, Hofmann WK, Haferlach C, Cross NCP, Fabarius A, Reiter A, Metzgeroth G Abstract P. 21st Congress Eur Hem Ass June , Copenhagen Age distribution of patients with myelodysplastic syndrome (MDS) in Germany and their prognosis according to the international prognostic scoring system (IPSS): Data from the regular care MDS registry. Steinmetz HT, Böttger I, Wahdat R, Haastert B, Sauer A, Lathan B, Germing U, Schmitz S Abstract P. 21st Congress Eur Hem Ass June , Copenhagen Mehr Eisen als uns gut tut Expertenbericht: Bei der Hämochromatose ist eine unspezifische Leberwerterhöhung wichtig für die Differenzialdiagnose. Golka K, Collette D, Claus M, Niedner H, Butzeck B Ärztewoche 28. April 2016, SpringerMedizin, Springer Verlag Heidelberg CONIFER Non-interventional study to evaluate therapy monitoring during Deferasirox treatment of iron toxicity in MDS patients with transfusional iron overload in the course of treatment. Tesch H, Bruch HR, Dencausse Y, Heßling J, Lerchenmüller C, Michel G, Schlag R, Skorupa A, Schneider-Schranz C, Wolf S, Schulte C DOI / Oncol Res Treat 2016, 39 (7-8): Abstract. 32. Deutscher Krebskongress Feb , Berlin Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase 3 rd interim analysis of the non-interventional MOMENT II-study. Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H Abstract P114. Deutscher Krebskongress Feb , Berlin 3

4 Hämochromatose Wichtige Differentialdiagnose der unspezifischen Leberwerterhöhung. CME Zertifizierte Fortbildung. Golka K, Collette D, Claus M, Niedner H, Butzeck B DOI /s Zbl Arbeitsmed 2016/3; 66: Monitoring of deferasirox treatment in patients with transfusion-dependent iron toxicity due to myelodysplastic syndromes. Tesch H, Schulte C, Bruch HR, Dencausse Y Poster. Centrum für Hämatologie und Onkologie Bethanien 2016, Frankfurt 2015 Ergebnisse einer Interimsanalyse der nicht-interventionellen MOMENT II-Studie zur Erfassung von Wirksamkeit und Sicherheit von Nilotinib bei neu diagnostizierten Ph+ CML-Patienten in chronischer Phase im klinischen Alltag. Lathan B, Sauer A, Ulshöfer T, Lange E, Tebbe S, Schulze M, Janssen J, Meincke M, Frank O, Tesch H Abstract P456. Jahrestagung DGHO Oct Berlin Assessment of the myelodysplasia (MDS) international prognostic scoring system (IPSS) in routine care: Data from the regular care MDS registry Steinmetz TH, Böttger I, Sauer A, Lathan B, Germing U, Schmitz S Abstract V606. Jahrestagung DGHO Oct Berlin 2014 Interim Results of a Phase 2 Study of MEDI-551 and Bendamustine vs. Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia. Gladstone DE, André M, Zaucha JM, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Streicher K, Bao H, Spaner D Abstract P th Ann Meeting Am Soc Hem Dec , San Francisco, CA 4

5 Phase 2 Open-Label Study of MEDI 551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL. Gladstone DE, André M, Zaucha JM, Araujo C, Assouline S, Bellam N, Cascavilla N, Jourdan E, Panwalkar A, Patti C, Schulte C, Zaja F, Goswami T, Elgeioushi N, Spaner D Abstract J Clin Oncol 2014; 32 (suppl 5) Results of an interim analysis of the non-interventional MOMENT II-study for determining efficacy and safety of Nilotinib in newly diagnosed Ph+ CML patients in chronic phase. Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H Abstract P215. Oncol Res Treat 2014; 37 (suppl 5): 63 Hämochromatose eine wichtige, selten gestellte Differentialdiagnose auch in der Arbeitsmedizin. Golka K, Collette D, Müller JF, Claus M, Niedner H, Butzeck B Umweltmed Hygiene Arbeitsmed 19 (2) 2014 Abstract P. Betriebl. Gesundheitsförderung/ Wiss. Jahrestagung der DGAUM April , Dresden Need of transfusion, treatment and survival of patients with Myelodysplastic Syndromes (MDS): Update oft he outpatient MDS registry Steinmetz TH, Böttger I, Lathan B, Sauer A, Severin K, Germing U, Schmitz S Abstract V. Jahrestagung DGHO Oct Hamburg 2013 Efficacy and safety of Nilotinib in routine clinical management of newly diagnosed Ph+ CML patients in chronic phase interim analysis of the non-interventional MOMENT II study. Lathan B, Sauer A, Titgemeyer J, Groschek M, Gabrysiak T, Hutzenreuter U, Tebbe S, Meincke M, Frank O, Tesch H Abstract P217. Onkologie 2013; 36 (suppl 7): 62 5